[Federal Register Volume 59, Number 179 (Friday, September 16, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-22995]
[[Page Unknown]]
[Federal Register: September 16, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Co-Exclusive License: Second Generation
Monoclonal Antibodies Having Binding Specificity to TAG-72 and Human
Carcinomas and Methods for Employing the Same
AGENCY: National Institutes of Health, Public Health Services, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
limited field of use co-exclusive worldwide licenses to practice the
invention embodied in U.S. Patent Applications Number 07/073,685 filed
on July 15, 1987 and Number 07/547,336 filed on July 20, 1990, entitled
``Second Generation Monoclonal Antibodies Having Binding Specificity to
TAG-72 and Human Carcinomas and Methods for Employing the Same'', to
Centocor, Inc., having a place of business in Malvern, PA, and to
Miles, Inc., having a place of business in Tarrytown, NY. The patent
rights in this invention have been assigned to the United States of
America.
The antibodies covered in this patent application have a higher
binding affinity and specificity to a tumor associated glycoprotein
(designated TAG-72) than previous monoclonal antibodies available
against TAG-72. The current antibodies also exhibit binding specificity
to more human carcinomas than the previous monoclonals, while
maintaining essentially no specificity to normal adult human tissues.
The prospective co-exclusive licenses will be royalty-bearing and
will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR
404.7. The prospective co-exclusive licenses may be granted unless,
within 60 days from the date of this published Notice, NIH receives
written evidence and argument that establishes that the grant of the
licenses would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR 404.7.
The field of use would be limited to in vitro non-
radioimmunodiagnostic assays utilizing TAG-72 antibody.
ADDRESSES: Requests for a copy of this patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Dr. Judith Plesset, Office of Technology
Transfer, National Institutes of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852-3804. Telephone: (301) 496-7735, ext
247; Facsimile: (301) 402-0220. A signed Confidential Disclosure
Agreement will be required to receive copies of the patent application.
Properly filed competing applications for a license filed in response
to this notice will be treated as objections to the contemplated
license. Only written comments and/or application for a license which
are received by the NIH Office of Technology Transfer on or before
November 15, 1994 will be considered.
Dated: August 31, 1994.
Barbara M. McGarey, J.D.,
Deputy Director, Office of Technology Transfer.
[FR Doc. 94-22995 Filed 9-15-94; 8:45 am]
BILLING CODE 4140-01-P
